Rat model of Parkinson's disease with bilateral motor abnormalities, reversible with levodopa, and dyskinesias
Identifieur interne : 000321 ( France/Analysis ); précédent : 000320; suivant : 000322Rat model of Parkinson's disease with bilateral motor abnormalities, reversible with levodopa, and dyskinesias
Auteurs : Vincent Paillé [France] ; Vincent Henry [France] ; Laurent Lescaudron [France] ; Philippe Brachet [France] ; Philippe Damier [France]Source :
- Movement Disorders [ 0885-3185 ] ; 2007-03-15.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
- 6‐OHDA, Akinesia, Animal model, Animals, Antiparkinson Agents (therapeutic use), Disease Models, Animal, Disease Progression, Dopamine (metabolism), Dyskinesia, Dyskinesias (diagnosis), Dyskinesias (drug therapy), Dyskinesias (physiopathology), Extremities (physiopathology), Levodopa, Levodopa (therapeutic use), Locus niger, Male, Mesencephalon (metabolism), Mesencephalon (pathology), Nerve Degeneration (metabolism), Nerve Degeneration (pathology), Nerve Degeneration (physiopathology), Nervous system diseases, Parkinson Disease (drug therapy), Parkinson Disease (pathology), Parkinson Disease (physiopathology), Parkinson disease, Parkinson's disease, Prosencephalon (metabolism), Prosencephalon (pathology), Rats, Rats, Sprague-Dawley, Severity of Illness Index, Substantia Nigra (metabolism), Substantia Nigra (pathology), Tyrosine 3-Monooxygenase (metabolism), akinesia, dyskinesias, levodopa, substantia nigra.
- MESH :
- chemical , metabolism : Dopamine, Tyrosine 3-Monooxygenase.
- chemical , therapeutic use : Antiparkinson Agents, Levodopa.
- diagnosis : Dyskinesias.
- drug therapy : Dyskinesias, Parkinson Disease.
- metabolism : Mesencephalon, Nerve Degeneration, Prosencephalon, Substantia Nigra.
- pathology : Mesencephalon, Nerve Degeneration, Parkinson Disease, Prosencephalon, Substantia Nigra.
- physiopathology : Dyskinesias, Extremities, Nerve Degeneration, Parkinson Disease.
- Animals, Disease Models, Animal, Disease Progression, Male, Rats, Rats, Sprague-Dawley, Severity of Illness Index.
Abstract
Parkinson's disease (PD) is characterized by the bilateral degeneration of the midbrain dopamine‐containing neurons with the most severe lesion in the posterolateral part of the substantia nigra pars compacta (SNpc). In humans, such lesions lead to specific motor abnormalities (i.e., akinesia, rigidity, and tremor) that are greatly improved by levodopa treatment. After a few years, the beneficial effect of the treatment is frequently offset by the development of dyskinesias. To improve treatment strategies, an animal model showing most of the histological and clinical characteristics of the human disease is mandatory. Ten rats received a bilateral injection of small doses of 6‐OHDA in the medial forebrain bundle (MFB) and were compared with five sham‐lesioned rats. The 6‐OHDA‐lesioned rats progressively developed abnormal motor behavior (assessed by the stepping test) compared with the sham‐lesioned rats. The lesioned rats greatly improved under levodopa treatment, but developed concomitant dyskinesias. All 6‐OHDA‐lesioned animals had bilateral partial lesions of the SNpc, with the most severe lesion being in its posterolateral part. There was a significant correlation between the severity of the dopaminergic cell loss and the severity of the levodopa‐induced dyskinesias. These rats constitute an interesting model of PD, sharing some of the main characteristics of the human disease. © 2006 Movement Disorder Society
Url:
DOI: 10.1002/mds.21308
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000857
- to stream Istex, to step Curation: 000857
- to stream Istex, to step Checkpoint: 001734
- to stream PubMed, to step Corpus: 002897
- to stream PubMed, to step Curation: 002897
- to stream PubMed, to step Checkpoint: 002597
- to stream Ncbi, to step Merge: 001A42
- to stream Ncbi, to step Curation: 001A42
- to stream Ncbi, to step Checkpoint: 001A42
- to stream Main, to step Merge: 003B48
- to stream PascalFrancis, to step Corpus: 001748
- to stream PascalFrancis, to step Curation: 001573
- to stream PascalFrancis, to step Checkpoint: 001493
- to stream Main, to step Merge: 004083
- to stream Main, to step Curation: 002C26
- to stream Main, to step Exploration: 002C26
- to stream France, to step Extraction: 000321
Links to Exploration step
ISTEX:E5D74CA8A007AC9F0101A7596D921ED625C80D09Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Rat model of Parkinson's disease with bilateral motor abnormalities, reversible with levodopa, and dyskinesias</title><author><name sortKey="Paille, Vincent" sort="Paille, Vincent" uniqKey="Paille V" first="Vincent" last="Paillé">Vincent Paillé</name></author><author><name sortKey="Henry, Vincent" sort="Henry, Vincent" uniqKey="Henry V" first="Vincent" last="Henry">Vincent Henry</name></author><author><name sortKey="Lescaudron, Laurent" sort="Lescaudron, Laurent" uniqKey="Lescaudron L" first="Laurent" last="Lescaudron">Laurent Lescaudron</name></author><author><name sortKey="Brachet, Philippe" sort="Brachet, Philippe" uniqKey="Brachet P" first="Philippe" last="Brachet">Philippe Brachet</name></author><author><name sortKey="Damier, Philippe" sort="Damier, Philippe" uniqKey="Damier P" first="Philippe" last="Damier">Philippe Damier</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:E5D74CA8A007AC9F0101A7596D921ED625C80D09</idno><date when="2007" year="2007">2007</date><idno type="doi">10.1002/mds.21308</idno><idno type="url">https://api.istex.fr/document/E5D74CA8A007AC9F0101A7596D921ED625C80D09/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000857</idno><idno type="wicri:Area/Istex/Curation">000857</idno><idno type="wicri:Area/Istex/Checkpoint">001734</idno><idno type="wicri:doubleKey">0885-3185:2007:Paille V:rat:model:of</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:17230470</idno><idno type="wicri:Area/PubMed/Corpus">002897</idno><idno type="wicri:Area/PubMed/Curation">002897</idno><idno type="wicri:Area/PubMed/Checkpoint">002597</idno><idno type="wicri:Area/Ncbi/Merge">001A42</idno><idno type="wicri:Area/Ncbi/Curation">001A42</idno><idno type="wicri:Area/Ncbi/Checkpoint">001A42</idno><idno type="wicri:doubleKey">0885-3185:2007:Paille V:rat:model:of</idno><idno type="wicri:Area/Main/Merge">003B48</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:07-0210954</idno><idno type="wicri:Area/PascalFrancis/Corpus">001748</idno><idno type="wicri:Area/PascalFrancis/Curation">001573</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">001493</idno><idno type="wicri:doubleKey">0885-3185:2007:Paille V:rat:model:of</idno><idno type="wicri:Area/Main/Merge">004083</idno><idno type="wicri:Area/Main/Curation">002C26</idno><idno type="wicri:Area/Main/Exploration">002C26</idno><idno type="wicri:Area/France/Extraction">000321</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Rat model of Parkinson's disease with bilateral motor abnormalities, reversible with levodopa, and dyskinesias</title><author><name sortKey="Paille, Vincent" sort="Paille, Vincent" uniqKey="Paille V" first="Vincent" last="Paillé">Vincent Paillé</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>INSERM, UMR 643 and Institut de Transplantation et de Recherche en Transplantation, CHU, Nantes</wicri:regionArea><placeName><settlement type="city">Nantes</settlement></placeName></affiliation><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>UFR de Médecine,Université de Nantes, Nantes</wicri:regionArea><placeName><settlement type="city">Nantes</settlement></placeName></affiliation></author><author><name sortKey="Henry, Vincent" sort="Henry, Vincent" uniqKey="Henry V" first="Vincent" last="Henry">Vincent Henry</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>INSERM, UMR 643 and Institut de Transplantation et de Recherche en Transplantation, CHU, Nantes</wicri:regionArea><placeName><settlement type="city">Nantes</settlement></placeName></affiliation><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>UFR de Médecine,Université de Nantes, Nantes</wicri:regionArea><placeName><settlement type="city">Nantes</settlement></placeName></affiliation></author><author><name sortKey="Lescaudron, Laurent" sort="Lescaudron, Laurent" uniqKey="Lescaudron L" first="Laurent" last="Lescaudron">Laurent Lescaudron</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>INSERM, UMR 643 and Institut de Transplantation et de Recherche en Transplantation, CHU, Nantes</wicri:regionArea><placeName><settlement type="city">Nantes</settlement></placeName></affiliation><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>UFR des Sciences et des Techniques,Université de Nantes, Nantes</wicri:regionArea><placeName><settlement type="city">Nantes</settlement></placeName></affiliation></author><author><name sortKey="Brachet, Philippe" sort="Brachet, Philippe" uniqKey="Brachet P" first="Philippe" last="Brachet">Philippe Brachet</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>INSERM, UMR 643 and Institut de Transplantation et de Recherche en Transplantation, CHU, Nantes</wicri:regionArea><placeName><settlement type="city">Nantes</settlement></placeName></affiliation><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>UFR de Médecine,Université de Nantes, Nantes</wicri:regionArea><placeName><settlement type="city">Nantes</settlement></placeName></affiliation></author><author><name sortKey="Damier, Philippe" sort="Damier, Philippe" uniqKey="Damier P" first="Philippe" last="Damier">Philippe Damier</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>INSERM, UMR 643 and Institut de Transplantation et de Recherche en Transplantation, CHU, Nantes</wicri:regionArea><placeName><settlement type="city">Nantes</settlement></placeName></affiliation><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>CHU Nantes, Clinique Neurologique and Centre d'Investigation Clinique, Nantes</wicri:regionArea><placeName><settlement type="city">Nantes</settlement></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2007-03-15">2007-03-15</date><biblScope unit="vol">22</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="533">533</biblScope><biblScope unit="page" to="539">539</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">E5D74CA8A007AC9F0101A7596D921ED625C80D09</idno><idno type="DOI">10.1002/mds.21308</idno><idno type="ArticleID">MDS21308</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>6‐OHDA</term><term>Akinesia</term><term>Animal model</term><term>Animals</term><term>Antiparkinson Agents (therapeutic use)</term><term>Disease Models, Animal</term><term>Disease Progression</term><term>Dopamine (metabolism)</term><term>Dyskinesia</term><term>Dyskinesias (diagnosis)</term><term>Dyskinesias (drug therapy)</term><term>Dyskinesias (physiopathology)</term><term>Extremities (physiopathology)</term><term>Levodopa</term><term>Levodopa (therapeutic use)</term><term>Locus niger</term><term>Male</term><term>Mesencephalon (metabolism)</term><term>Mesencephalon (pathology)</term><term>Nerve Degeneration (metabolism)</term><term>Nerve Degeneration (pathology)</term><term>Nerve Degeneration (physiopathology)</term><term>Nervous system diseases</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (pathology)</term><term>Parkinson Disease (physiopathology)</term><term>Parkinson disease</term><term>Parkinson's disease</term><term>Prosencephalon (metabolism)</term><term>Prosencephalon (pathology)</term><term>Rats</term><term>Rats, Sprague-Dawley</term><term>Severity of Illness Index</term><term>Substantia Nigra (metabolism)</term><term>Substantia Nigra (pathology)</term><term>Tyrosine 3-Monooxygenase (metabolism)</term><term>akinesia</term><term>dyskinesias</term><term>levodopa</term><term>substantia nigra</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Dopamine</term><term>Tyrosine 3-Monooxygenase</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Dyskinesias</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Dyskinesias</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Mesencephalon</term><term>Nerve Degeneration</term><term>Prosencephalon</term><term>Substantia Nigra</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Mesencephalon</term><term>Nerve Degeneration</term><term>Parkinson Disease</term><term>Prosencephalon</term><term>Substantia Nigra</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Dyskinesias</term><term>Extremities</term><term>Nerve Degeneration</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Disease Models, Animal</term><term>Disease Progression</term><term>Male</term><term>Rats</term><term>Rats, Sprague-Dawley</term><term>Severity of Illness Index</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Akinésie</term><term>Dyskinésie</term><term>Locus niger</term><term>Lévodopa</term><term>Modèle animal</term><term>Parkinson maladie</term><term>Système nerveux pathologie</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Parkinson's disease (PD) is characterized by the bilateral degeneration of the midbrain dopamine‐containing neurons with the most severe lesion in the posterolateral part of the substantia nigra pars compacta (SNpc). In humans, such lesions lead to specific motor abnormalities (i.e., akinesia, rigidity, and tremor) that are greatly improved by levodopa treatment. After a few years, the beneficial effect of the treatment is frequently offset by the development of dyskinesias. To improve treatment strategies, an animal model showing most of the histological and clinical characteristics of the human disease is mandatory. Ten rats received a bilateral injection of small doses of 6‐OHDA in the medial forebrain bundle (MFB) and were compared with five sham‐lesioned rats. The 6‐OHDA‐lesioned rats progressively developed abnormal motor behavior (assessed by the stepping test) compared with the sham‐lesioned rats. The lesioned rats greatly improved under levodopa treatment, but developed concomitant dyskinesias. All 6‐OHDA‐lesioned animals had bilateral partial lesions of the SNpc, with the most severe lesion being in its posterolateral part. There was a significant correlation between the severity of the dopaminergic cell loss and the severity of the levodopa‐induced dyskinesias. These rats constitute an interesting model of PD, sharing some of the main characteristics of the human disease. © 2006 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>France</li></country><settlement><li>Nantes</li></settlement></list><tree><country name="France"><noRegion><name sortKey="Paille, Vincent" sort="Paille, Vincent" uniqKey="Paille V" first="Vincent" last="Paillé">Vincent Paillé</name></noRegion><name sortKey="Brachet, Philippe" sort="Brachet, Philippe" uniqKey="Brachet P" first="Philippe" last="Brachet">Philippe Brachet</name><name sortKey="Brachet, Philippe" sort="Brachet, Philippe" uniqKey="Brachet P" first="Philippe" last="Brachet">Philippe Brachet</name><name sortKey="Damier, Philippe" sort="Damier, Philippe" uniqKey="Damier P" first="Philippe" last="Damier">Philippe Damier</name><name sortKey="Damier, Philippe" sort="Damier, Philippe" uniqKey="Damier P" first="Philippe" last="Damier">Philippe Damier</name><name sortKey="Henry, Vincent" sort="Henry, Vincent" uniqKey="Henry V" first="Vincent" last="Henry">Vincent Henry</name><name sortKey="Henry, Vincent" sort="Henry, Vincent" uniqKey="Henry V" first="Vincent" last="Henry">Vincent Henry</name><name sortKey="Lescaudron, Laurent" sort="Lescaudron, Laurent" uniqKey="Lescaudron L" first="Laurent" last="Lescaudron">Laurent Lescaudron</name><name sortKey="Lescaudron, Laurent" sort="Lescaudron, Laurent" uniqKey="Lescaudron L" first="Laurent" last="Lescaudron">Laurent Lescaudron</name><name sortKey="Paille, Vincent" sort="Paille, Vincent" uniqKey="Paille V" first="Vincent" last="Paillé">Vincent Paillé</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/France/Analysis
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000321 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/France/Analysis/biblio.hfd -nk 000321 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= France
|étape= Analysis
|type= RBID
|clé= ISTEX:E5D74CA8A007AC9F0101A7596D921ED625C80D09
|texte= Rat model of Parkinson's disease with bilateral motor abnormalities, reversible with levodopa, and dyskinesias
}}
| This area was generated with Dilib version V0.6.23. |  |